Liraglutide

Evidence

Liraglutide

GLP-1 Receptor Agonist • W eight Management • Type 2 Diabetes

At a Glance

What is Liraglutide?

Liraglutide is a GLP-1 receptor agonist .

It copies some of the effects of a natural hormone called GLP-1.

GLP-1 helps control:

• appetite

• fullness

• blood sugar

• insulin release

• glucagon release

• how quickly food leaves the stomach

Natural GLP-1 disappears from the body very quickly.

Liraglutide was designed to last much longer.

Its half-life is about:

13 hours which makes:

once-daily dosing possible.

Liraglutide is the active ingredient in products used for different purposes, including:

• Saxenda for long-term weight management

• Victoza and other liraglutide diabetes products for type 2 diabetes

How well studied is it?

V ery well studied in humans Liraglutide is one of the better-studied compounds in this library.

It has:

• large randomized human trials

• FDA-approved products

• established clinical dosing

• long-term human follow-up

• cardiovascular research

• pediatric studies

• well-described safety information

Major weight-management trials commonly lasted:

56 weeks and some participants were followed for up to:

160 weeks Evidence level Approved-label human evidence: Very strong Human clinical research: Very strong W eight-management evidence: Strong Type 2 diabetes evidence: Strong Community protocols: Secondary because strong clinical protocols already exist

What may it help with?

Strong human evidence

Weight Loss and Long-Term Weight Management

Saxenda is FDA approved, together with diet and physical activity, to help eligible adults and adolescents lose excess weight and maintain weight reduction.

In one major 56-week obesity trial, average weight loss was about:

8.4 kg with liraglutide 3 mg compared with:

2.8 kg with placebo

Reduced Appetite and Increased Fullness

Liraglutide helps reduce food intake.

It can:

• decrease appetite

• increase fullness

• make it easier to stop eating sooner

This is one of the main reasons it helps with weight management.

Blood Sugar Control

Liraglutide is also FDA approved to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes.

Clinical Research

First F ew W eeks Appetite and fullness may start changing while the dose is being increased.

But the first four weeks are also the titration period, so early weight-loss results can vary.

Around 16 W eeks The current Saxenda label uses an important adult checkpoint at:

16 weeks after starting treatment If an adult has not lost at least:

4% of starting body weight

by this point, the label recommends stopping treatment because meaningful long-term weight loss is unlikely.

Around 56 W eeks Major weight-management studies commonly measured their main results at:

56 weeks In the SCALE obesity trial:

Liraglutide: about 8.4 kg average weight loss Placebo: about 2.8 kg average weight loss Up to 160 W eeks Some participants with abnormal blood sugar measurements were followed for up to:

160 weeks Clinical T akeaway For weight management:

think in months, not days.

Community-Reported Timeline

Community experiences commonly describe:

Days to a few weeks: less hunger or feeling full sooner Several weeks: gradual changes on the scale Several months: more noticeable changes in body weight and waist size Important These are community descriptions.

They are not controlled averages from clinical trials .

Because liraglutide already has strong clinical research, the clinical timeline should remain the main timeline on the page.

Simple Timeline for the T op Card Clinical: appetite changes may begin during titration, adult response is checked at 16 weeks , major weight-loss results are commonly measured around 56 weeks, and some research extends to 160 weeks .

Community-reported: appetite changes are often noticed before major weight changes, which usually develop over weeks to months .

Regulatory Status at a Glance

FDA approved?

Y es Saxenda approved for Long-term weight management in eligible adults and adolescents Diabetes liraglutide approved for Type 2 diabetes treatment, with cardiovascular-risk reduction in certain adults with established cardiovascular disease Approved route Subcutaneous Adult Saxenda maintenance dose 3 mg once daily General bodybuilding approval?

No

Athletic-performance approval?

No

Bottom Line

Liraglutide is very well studied, and its main dosing protocols are already established by large human trials and FDA labeling.

For adult weight management, the best-supported Saxenda protocol is:

W eek 1: 0.6 mg daily W eek 2: 1.2 mg daily W eek 3: 1.8 mg daily W eek 4: 2.4 mg daily W eek 5 onward: 3 mg daily For type 2 diabetes, the dosing is different:

0.6 mg → 1.2 mg → up to 1.8 mg daily The two protocols should not be mixed together.

For adult Saxenda:

1.8 mg is a titration dose.

2.4 mg is a titration dose.

3 mg is the recommended maintenance dose.

Quick Logic Summary

Protocol Question Verdict Once-daily dosing? Y es, strongly supported Subcutaneous route? Y es, strongly supported ~13-hour half-life? Y es Saxenda 0.6 → 3 mg titration? Y es, evidence-supported 3 mg adult Saxenda maintenance? Y es Diabetes 0.6 → 1.2 → 1.8 mg? Y es 1.8 mg as universal liraglutide maintenance?

No, depends on indication 2.4 mg as a “fat-loss threshold”? No

Protocol Question Verdict Bedtime dosing better? Not shown Fasted dosing needed? No Only taking it when hungry? Not supported Every-other-day dosing? Not supported Twice-daily split dosing? Not supported 8–12 week cycle? No proven reason Receptor reset? No proven requirement Combine with another GLP-1 drug? Not recommended Research vial = approved pen? No

What Does Liraglutide Target?

Liraglutide activates the:

GLP-1 receptor Simple V ersion GLP-1 signaling helps tell the body:

• food has arrived

• release insulin when needed

• reduce unnecessary glucagon

• slow digestion

• increase fullness

• reduce the urge to keep eating

V erdict W ell established

How Long Does It Stay in the Body?

Liraglutide has a half-life of about:

13 hours After a Saxenda injection, the drug reaches its highest blood level at about:

11 hours

Why This Matters This long exposure is why liraglutide is designed for:

one injection every day rather than:

• several injections per day

• every-other-day use

• once-weekly use

V erdict Once-daily dosing is strongly supported.

How Long Do the Effects Last?

Natural GLP-1 lasts only a few minutes.

Liraglutide was designed to resist rapid breakdown and stay active much longer.

One daily injection provides clinically useful GLP-1 signaling across the day.

V erdict Evidence-supported

Does It Build Up With Daily Use?

Daily dosing creates steady repeated exposure.

The tested clinical schedule is:

one dose every day rather than:

• large doses separated by long gaps

• irregular dosing

• only taking it when hunger returns

V erdict Daily use matches the studied pharmacology .

Does the Route Match the Research?

Saxenda SC Diabetes Liraglutide SC Major Human T rials SC V erdict Y es, strongly supported

Important Research Note

Three different liraglutide situations are often mixed together online.

1. Saxenda

Used for:

long-term weight management Adult Maintenance 3 mg once daily after titration.

2. Victoza / Diabetes Liraglutide

Used for:

type 2 diabetes Typical adult treatment doses are:

1.2 mg

or:

1.8 mg once daily

3. Research / Compounded Liraglutide

A research vial or compounded product should not automatically inherit:

• Saxenda storage

• Saxenda concentration

• Saxenda sterility

• pen dosing accuracy

• 30-day in-use stability

from the approved pen.

Research at a Glance

Approved-Label Human Evidence

V ery Strong Liraglutide has detailed FDA labeling for both weight management and diabetes.

Human Clinical Research

V ery Strong Large human studies support effects on:

• body weight

• blood sugar

• cardiovascular outcomes

• long-term treatment

Observational Human Evidence

Extensive Years of medical use provide a large amount of real-world safety experience.

Animal / Cell Evidence

Supporting Especially useful for understanding the thyroid C-cell tumor warning.

Mechanistic Evidence

Strong GLP-1 receptor biology is well understood.

Community / Anecdotal Evidence

Secondary Community experience can help explain real-world tolerability.

But for liraglutide, strong clinical evidence matters much more.

Overview

Liraglutide is a long-acting GLP-1 receptor agonist.

Depending on the product and dose, it is used medically for:

• long-term weight management

• type 2 diabetes

It is given:

once daily by subcutaneous injection Its weight-management effects mainly come from:

• reducing appetite

• increasing fullness

• lowering food intake

It also affects:

• insulin

• glucagon

• blood sugar

• stomach emptying

Important Liraglutide mainly helps people:

eat less It has not been shown to work by dramatically increasing how many calories the body burns.

Evidence Strength

Overall Evidence Rating

Strong human evidence Strong evidence for

• GLP-1 receptor activation

• reduced appetite

• weight loss

• long-term weight management

• type 2 diabetes treatment

• once-daily SC dosing

• gradual titration

• cardiovascular benefit in specific diabetes populations

• major safety risks

Limited or Unproven F or

• only taking it when hungry

• every-other-day use

• bedtime superiority

• fasting superiority

• split dosing

• bodybuilding

• athletic enhancement

• spot fat loss

• receptor-reset cycles

• stacking with other GLP-1 drugs

Category

GLP-1 Receptor Agonists / W eight Management / Metabolic Health

Compound

Liraglutide Major branded products include:

• Saxenda

• Victoza

Compound Type

Long-acting GLP-1 receptor agonist Liraglutide is:

• peptide-based

• an incretin mimetic

• a GLP-1 receptor agonist

It is not:

• insulin

• a stimulant

• a GIP agonist

• a glucagon agonist

Primary Research Focus

Best Established

• long-term weight management

• type 2 diabetes

• appetite reduction

• blood sugar control

• cardiovascular-risk reduction in selected diabetes patients

Also Studied

• waist circumference

• blood pressure

• lipid markers

• prediabetes

• long-term obesity treatment

Not Established

• athletic performance

• bodybuilding

• spot fat loss

• injury repair

• only taking it when appetite returns

How It Works / Receptor Mechanism

Liraglutide activates the:

GLP-1 receptor Simple V ersion After food enters the body, natural GLP-1 helps send the message:

food is coming in, so control blood sugar and reduce the drive to keep eating.

Liraglutide creates a much longer-lasting version of that signal.

Main Effects Pancreas: helps release insulin when blood sugar is elevated Glucagon: reduces unnecessary glucagon release Stomach: slows stomach emptying Brain: increases fullness and reduces appetite

Possible Benefits

Strong Human Evidence

W eight Loss Large randomized human studies show meaningful average weight loss with:

liraglutide 3 mg plus lifestyle changes.

Appetite Reduction Reduced appetite and increased fullness are central effects of GLP-1 treatment.

Better Blood Sugar Control Strongly established in type 2 diabetes.

Cardiovascular Outcomes Liraglutide has cardiovascular benefit in adults with:

• type 2 diabetes

• established cardiovascular disease

Some Additional Human Evidence

W aist Circumference Saxenda trials found greater reductions in waist circumference than placebo.

Blood Pressure Obesity studies found modest average improvements in blood pressure.

Lipids and Other Metabolic Measures Some other cardiometabolic measurements also improved.

These should be presented as:

secondary outcomes rather than the main reason liraglutide works.

What It Does Not Help With, Based on Current

Evidence

Do not present liraglutide as proven to:

• specifically target belly fat

• build muscle

• improve athletic performance

• increase energy

• repair injuries

• directly speed up metabolism

• produce the same weight loss at every dose

• permanently prevent weight regain after stopping

Commonly Paired With

Metformin

Frequently used with liraglutide in type 2 diabetes.

Classification: Clinically established combination.

Insulin

Can be used clinically in selected patients.

Classification: Clinically established in some situations, but low blood sugar risk and dose management matter.

Other GLP-1 Agonists

Examples include semaglutide.

Classification: Not recommended because the pathways overlap.

Tirzepatide / Retatrutide

Both include GLP-1 receptor activity.

Classification: Major pathway overlap; no established routine combination.

Cagrilintide

Uses a different receptor system.

Classification: Different mechanism, but no validated liraglutide combination protocol.

Dosage Information

Saxenda

Product: Saxenda Compound: Liraglutide Strength: 18 mg / 3 mL Concentration: 6 mg/mL F orm: Clear, colorless liquid Route: Subcutaneous Device: Single-patient-use prefilled pen

Human Clinical Research

Early W eeks Liraglutide starts working right away.

But Saxenda spends the first month gradually increasing toward the maintenance dose.

Appetite changes may happen before full-dose treatment is reached.

W eek 16 Adult response should be checked.

If body weight has not dropped by at least:

4% from the starting weight, the current label recommends stopping Saxenda.

W eek 56 Large obesity trials show meaningful average weight loss by about:

1 year Up to W eek 160 Some participants remained in longer-term research for about:

160 weeks

Community-Reported

Common descriptions include:

Days to weeks: less appetite or feeling full sooner Several weeks: changes on the scale Several months: more noticeable changes in body weight and waist size Evidence W arning Community timelines should remain secondary because liraglutide already has strong human outcome data.

Regulatory Status

United States

FDA approved Saxenda Approved for long-term weight management in eligible adults and adolescents.

Victoza / Diabetes Liraglutide Approved for type 2 diabetes, with cardiovascular-risk reduction in certain adults with established cardiovascular disease.

Approved Route Subcutaneous Not Approved F or

• bodybuilding

• athletic performance

• spot fat loss

• only taking it when hungry

• routine combination with another GLP-1 agonist

What Studies Have Found

SCALE Obesity and Prediabetes

A large randomized trial compared:

liraglutide 3 mg once daily with placebo alongside lifestyle changes.

At 56 weeks:

Liraglutide: about 8.4 kg average weight loss Placebo: about 2.8 kg average weight loss What This Supports

• 3 mg adult weight-management dosing

• once-daily use

• long-term treatment

• meaningful average weight loss

What It Does Not Support

• only taking it when hungry

• random microdosing

• every-other-day dosing

• assuming 0.6 mg gives the same long-term effect

SCALE Diabetes

Adults with type 2 diabetes were assigned to:

• liraglutide 3 mg

• liraglutide 1.8 mg

• placebo

A verage weight loss was about:

6.4 kg with 3 mg 5.0 kg with 1.8 mg 2.2 kg with placebo What This Supports Dose can affect weight-loss results.

What It Does Not Support Treating:

1.8 mg and 3 mg as if they are interchangeable protocols.

Long-Term Weight Management Research

Saxenda trials commonly lasted:

56 weeks with some participants followed for:

160 weeks

What This Supports Liraglutide is designed as a:

long-term treatment rather than a short peptide cycle.

Cardiovascular Research

Liraglutide has been studied in adults with:

• type 2 diabetes

• established cardiovascular disease

The diabetes indication includes reducing major cardiovascular events in this specific population.

What This Supports Cardiovascular benefit in the:

type 2 diabetes population that was actually studied What It Does Not Support Automatically giving Saxenda a general cardiovascular-disease indication for everyone using it for weight management.

Research / Compounded Liraglutide

Do not automatically apply Saxenda’s:

• 6 mg/mL concentration

• 30-day storage rule

• sterility

• pen accuracy

to:

• research vials

• compounded multidose vials

• lyophilized liraglutide

• products mixed with bacteriostatic water

Simple Rule Use storage and handling instructions for the exact product.

Dosing evidence

Dose at a Glance

Clinical / FDA-Approved Dosing

There are two major liraglutide dosing systems .

They should not be mixed together.

Saxenda for Weight Management

Adult Titration W eek 1: 0.6 mg once daily W eek 2: 1.2 mg once daily W eek 3: 1.8 mg once daily W eek 4: 2.4 mg once daily W eek 5 onward: 3 mg once daily Adult Maintenance Dose 3 mg SC once daily For adults, the lower doses are used to gradually work up to 3 mg.

If a dose increase is not tolerated, the next increase can be delayed by about:

1 extra week If an adult cannot tolerate:

3 mg daily the current Saxenda label says treatment should be discontinued.

Victoza / Diabetes Liraglutide

Adults W eek 1: 0.6 mg once daily Then:

1.2 mg once daily If more blood sugar control is needed:

1.8 mg once daily after at least one week at 1.2 mg.

Important The:

0.6 mg dose is mainly a starting dose to reduce stomach-related side effects.

In adults, it is not considered an effective dose for blood sugar control .

Research-Community Dosing

Liraglutide is different from many research compounds because its clinical dosing is already well established.

Community practices sometimes include:

• staying at a lower dose longer

• increasing more slowly because of nausea

• staying below 3 mg because appetite is already strongly reduced

Evidence level Community modification of an established clinical protocol Slower increases for tolerability can make sense.

But for adult Saxenda:

staying permanently below 3 mg is not the current FDA-approved weight-management protocol.

Frequency at a Glance

Clinical

Once daily This applies to both:

• Saxenda

• diabetes liraglutide products

T wice daily?

Not established

Every other day?

Not established 5 days on / 2 days off?

Not established Only when hungry?

Not established Best-supported frequency Once daily

Timing at a Glance

Clinical

Liraglutide can be taken:

at any time of day and:

with or without food It is injected under the skin into the:

• abdomen

• thigh

• upper arm

Injection sites should be rotated.

Evidence verdict Morning required: No Night required: No F asted required: No With food required: No Pre-workout required: No Post-workout required: No

Duration / Cycle at a Glance

Clinical

Liraglutide is designed for:

ongoing treatment rather than short peptide-style cycles.

Major weight-management studies lasted about:

56 weeks with some longer research extending to:

160 weeks Does it need to be cycled?

No receptor-reset cycle has been established.

There is no proven need for:

• 8 weeks on / 4 weeks off

• 12-week cycles

• 5 days on / 2 days off

• 2–4 week receptor resets

Expected Results Timeline

Protocol Logic Check

Does Once-Daily Dosing Make Sense?

Yes.

Both major liraglutide uses are built around:

once-daily SC dosing V erdict Strongly evidence-supported

Does Twice-Daily Dosing Make Sense?

There is no established benefit to splitting liraglutide into:

• a morning dose

• an evening dose

V erdict Not supported

Does Every-Other-Day Dosing Make Sense?

Not as a validated protocol.

Liraglutide was designed and studied for:

once-daily use Skipping a full day creates larger swings in drug exposure than the tested daily schedule.

V erdict Not supported

Does Bedtime Dosing Work Better?

The label allows liraglutide at:

any time of day There is no established evidence that bedtime produces better:

• weight loss

• appetite reduction

• blood sugar control

V erdict No demonstrated advantage

Does It Need to Be Taken Fasted?

No.

Liraglutide can be taken:

with or without food V erdict Not required

Pre-Workout or Post-Workout Timing

There is no established benefit to taking liraglutide:

• before exercise

• after exercise

V erdict No demonstrated reason

Dose Escalation / Titration

For liraglutide, titration is actually supported by clinical evidence and labeling.

Saxenda starts at:

0.6 mg and increases weekly until:

3 mg The slow increase is mainly used to reduce stomach-related side effects.

V erdict Evidence-supported This is different from compounds where titration is only a community habit.

Is 1.8 mg the Standard Maintenance Dose?

F or Type 2 Diabetes It can be.

Diabetes liraglutide can use:

1.2 mg or:

1.8 mg depending on blood sugar control.

F or Adult Saxenda W eight Management No.

The recommended adult maintenance dose is:

3 mg daily The:

1.8 mg dose is part of the titration schedule.

V erdict It depends on what liraglutide is being used for.

This is one of the biggest corrections needed on the live page.

Is 2.4 mg a “Fat-Loss Threshold”?

No.

For adult Saxenda:

2.4 mg is the week-4 titration dose.

It is not officially described as:

“the fat-loss threshold. ”

V erdict Remove that wording.

Does It Need an 8–12 Week Cycle?

No.

Clinical studies lasted much longer, including:

• 56 weeks

• up to 160 weeks in some participants

V erdict No short-cycle requirement

Does the GLP-1 Receptor Need a Reset?

Some effects of GLP-1 drugs can change with long-term treatment.

For example, the effect on stomach emptying may become less pronounced over time.

That does not mean the GLP-1 receptor needs a scheduled break.

Long-term weight-management benefit has been shown with continued treatment.

V erdict No established receptor-reset requirement

Does It Need a Washout?

There is no validated:

• 2-week washout

• 4-week break

• receptor recovery period

for ongoing liraglutide treatment.

V erdict No demonstrated requirement

Can It Be Taken Only When Hunger Returns?

That does not match the tested clinical protocol.

Liraglutide is intended for:

consistent once-daily use V erdict Not supported

Common Research Dose

Weight Management

Saxenda 0.6 → 1.2 → 1.8 → 2.4 → 3 mg SC once daily

Type 2 Diabetes

Victoza / Diabetes Liraglutide 0.6 → 1.2 → up to 1.8 mg SC once daily

Research Duration / Cycle Length

Weight Management

Clinical studies commonly lasted:

56 weeks with some participants followed for:

160 weeks Evidence Assessment Liraglutide is designed for:

long-term treatment There is no established receptor-reset cycle.

How Often It Is Used / Frequency

Clinical

Once daily There is no established benefit from:

• twice-daily use

• every-other-day use

• 5-on / 2-off schedules

• only taking it when hungry

Adult Dose Escalation

W eek 1: 0.6 mg daily W eek 2: 1.2 mg daily W eek 3: 1.8 mg daily W eek 4: 2.4 mg daily W eek 5 onward: 3 mg daily Why Increase Slowly?

Mainly to reduce stomach-related side effects.

Timing

Inject:

once daily at any time with or without food.

Injection Sites

• abdomen

• thigh

• upper arm

Rotate injection sites.

Missed Dose

If one dose is missed:

take the next dose at the normal scheduled time.

Do not take an extra dose.

If more than:

3 days have passed since the last Saxenda dose:

restart at:

0.6 mg daily and repeat the dose-escalation schedule to reduce GI side effects.

Victoza / Diabetes Liraglutide Dosing

Adults

Start: 0.6 mg SC once daily for one week Then:

1.2 mg daily If more blood sugar control is needed:

1.8 mg daily after at least one week at 1.2 mg.

Important Do not copy:

Saxenda’s 3 mg maintenance dose into the diabetes protocol.

Likewise, do not call:

1.8 mg the standard adult Saxenda maintenance dose.

Community Research Protocol

Because liraglutide already has a detailed approved protocol, community use usually involves:

changing how quickly the dose is increased rather than creating a completely different dosing system.

Common community practices include:

• staying at one dose longer if nausea is strong

• increasing more slowly

• not increasing while appetite suppression remains strong

Evidence Check Slower escalation for tolerability: Makes sense and fits the reason titration exists Delaying an increase by about one extra week: Supported by the Saxenda label if a higher dose is not tolerated Staying below 3 mg indefinitely for adult Saxenda: Community / offlabel practice Only taking it when hungry: Unsupported Every-other-day dosing: Unsupported

Community Protocol Comparison

Protocol Dose Frequency Purpose Evidence Saxenda week 1 0.6 mg Daily SC Titration FDA label Saxenda week 2 1.2 mg Daily SC Titration FDA label Saxenda week 3 1.8 mg Daily SC Titration FDA label Saxenda week 4 2.4 mg Daily SC Titration FDA label Saxenda maintenance 3 mg Daily SC Weight management FDA label Diabetes liraglutide 1.2–1.8 mg Daily SC Type 2 diabetes FDA label

Protocol Dose Frequency Purpose Evidence Slower community titration Variable Daily SC Tolerability Community / reasonable PRN or EOD use Variable Irregular Appetite Unsupported Strongest Agreement Once-daily SC use with gradual titration Main Source of Confusion People often mix together:

• Saxenda doses

• Victoza doses

• titration doses

• maintenance doses

They should stay separate.

Expected Results Timeline, Expanded

Contraindications

Cardiovascular Risk Reduction in Certain People With

Type 2 Diabetes

Diabetes-dose liraglutide also has an FDA indication to reduce major cardiovascular events in adults who have:

• type 2 diabetes

• established cardiovascular disease

This should not automatically be applied to everyone using Saxenda only for weight management.

What has it NOT been proven to help with?

Liraglutide has not been established as a treatment for:

• bodybuilding

• muscle growth

• athletic performance

• injury recovery

• spot fat loss

• selectively burning belly fat

• directly increasing metabolism

• guaranteed energy improvement

• occasional “as needed” appetite control

• producing the same weight-loss result at every dose

For adults using Saxenda for weight management:

3 mg daily is the recommended maintenance dose.

Lower doses are used while the dose is gradually increased.

Safety at a Glance

Common or Important Effects

Common Saxenda effects include:

• nausea

• diarrhea

• constipation

• vomiting

• injection-site reactions

• headache

• indigestion

• fatigue

• dizziness

• abdominal pain

• increased lipase

Stomach-related side effects are especially common while the dose is being increased.

Important Safety Concerns

Thyroid C-Cell T umors Liraglutide caused thyroid C-cell tumors in animal studies.

It is not known whether it causes these tumors in humans.

Because of this, Saxenda should not be used by people with:

• a personal or family history of medullary thyroid carcinoma

• MEN 2

Pancreatitis Acute pancreatitis has been reported with GLP-1 receptor agonists including liraglutide.

Severe or ongoing abdominal pain should be medically evaluated.

Gallbladder Disease Liraglutide can increase the risk of:

• gallstones

• gallbladder inflammation

Hypoglycemia Low blood sugar is especially important when liraglutide is combined with:

• insulin

• sulfonylureas

• other medicines that increase insulin release

Increased Heart Rate Saxenda can increase resting heart rate.

Kidney Injury F rom Dehydration Severe or ongoing:

• nausea

• vomiting

• diarrhea

can lead to dehydration.

That dehydration can contribute to acute kidney injury.

Severe Stomach and Digestive Effects Saxenda can cause severe gastrointestinal side effects.

It is not recommended for people with severe gastroparesis .

Serious Allergic Reactions Serious reactions including:

• anaphylaxis

• angioedema

have been reported.

Aspiration During Anesthesia or Deep Sedation Liraglutide can slow stomach emptying.

That means food may remain in the stomach longer.

Rare aspiration events have been reported during procedures involving:

• general anesthesia

• deep sedation

People taking liraglutide should tell the medical team before surgery or sedation.

Major Contraindications

Formal FDA Contraindications

Personal or F amily History of Medullary Thyroid Carcinoma Contraindicated MEN 2 Contraindicated Serious Allergy to Liraglutide or Product Ingredients Contraindicated

Important 2026 Safety Update

Older Saxenda information may still list:

suicidal behavior or suicidal thoughts

as a warning.

That information is now outdated.

In February 2026, FDA approved removal of this warning from Saxenda’s prescribing information.

FDA’s broader review found that the available evidence did not support a causal link between GLP-1 receptor agonists and suicidal thoughts or behavior.

What Navaro Should Do The current live page should not list:

“History of suicidal ideation or prior suicide attempts” as a current Saxenda contraindication or risk flag.

If mentioned at all, it should only appear as a:

historical regulatory note

Contraindications & Cautions

Formal Contraindications

Personal or F amily History of MTC Contraindicated MEN 2 Contraindicated Serious Hypersensitivity to Liraglutide Contraindicated

Important Cautions

Pancreatitis Pancreatitis is an important warning.

But:

a history of pancreatitis is not listed as a formal current Saxenda contraindication.

Severe Gastroparesis Saxenda is:

not recommended rather than formally contraindicated.

Kidney Disease / Dehydration Risk Kidney impairment itself is not a blanket contraindication.

The main concern is kidney injury caused or worsened by dehydration from severe GI side effects.

Diabetes Medications Insulin and sulfonylureas can increase the risk of low blood sugar.

Pregnancy Pregnancy is not currently listed as a formal Saxenda contraindication.

But that does not mean Saxenda should be continued during pregnancy.

Weight loss provides no benefit during pregnancy, the label warns of possible fetal harm, and Saxenda should be:

stopped when pregnancy is recognized.

Planned Surgery / Deep Sedation Tell the procedural team about liraglutide because it can slow stomach emptying.

Suicidal Ideation This is:

no longer a current Saxenda warning FDA approved removal of the warning in February 2026.

Side effects

Reported Side Effects

Common Effects

• nausea

• diarrhea

• constipation

• vomiting

• injection-site reactions

• headache

• indigestion

• fatigue

• dizziness

• abdominal pain

• increased lipase

Pancreatitis

Acute pancreatitis has occurred with liraglutide.

Severe or persistent abdominal pain needs medical assessment.

Gallbladder Disease

Known risks include:

• gallstones

• gallbladder inflammation

Hypoglycemia

Most relevant when liraglutide is combined with:

• insulin

• sulfonylureas

rather than liraglutide alone.

Heart-Rate Increase

Saxenda can increase resting heart rate.

Kidney Injury From Dehydration

Severe stomach-related side effects can cause dehydration.

That dehydration can contribute to acute kidney injury.

Severe GI Effects

Saxenda is:

not recommended in severe gastroparesis

Serious Allergic Reactions

Serious allergic reactions including:

• anaphylaxis

• angioedema

have been reported.

Aspiration During Anesthesia

Because liraglutide can slow stomach emptying, food may remain in the stomach longer than expected.

Rare aspiration cases have been reported during anesthesia or deep sedation.

Compatibility

Stack / Pairing Logic

Liraglutide + Semaglutide Both activate the GLP-1 receptor.

The Saxenda label says using another GLP-1 receptor agonist at the same time is:

not recommended

V erdict T oo much pathway overlap and not recommended Liraglutide + Tirzepatide Tirzepatide also includes GLP-1 receptor activity, along with GIP activity.

V erdict Major pathway overlap; no validated routine combination Liraglutide + Retatrutide Retatrutide also includes GLP-1 receptor activity.

V erdict Major pathway overlap; no validated routine combination Liraglutide + Cagrilintide Cagrilintide works through a different main pathway.

V erdict Different mechanism, but no established liraglutide combination protocol Liraglutide + Insulin This combination can be used clinically in selected people with diabetes.

But:

• the injections should remain separate

• they should not be mixed

• low blood sugar risk needs to be considered

V erdict Clinically used in selected situations with medical management

Source url

Research Sources

Use clean canonical URLs in production .

1. DailyMed: Saxenda Evidence type: Current FDA-approved labeling Supports:

• weight-management indication

• 0.6 → 3 mg escalation

• adult 3 mg maintenance

• once-daily SC route

• meal-independent timing

• contraindications

• current warnings

• 16-week adult response check

• formulation

• storage

• 30-day in-use period

• current 2026 warning structure

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 2. DailyMed: Victoza Evidence type: FDA-approved diabetes labeling Supports:

• 0.6 mg starting dose

• 1.2 mg treatment dose

• optional increase to 1.8 mg

• once-daily SC use

• any-time-of-day dosing

• meal-independent dosing

• type 2 diabetes indication

• cardiovascular-risk reduction in adults with type 2 diabetes and estab-

lished cardiovascular disease

• approximately 13-hour half-life

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 3. Pi-Sunyer et al.: SCALE Obesity and Prediabetes Evidence type: Randomized human clinical trial

Supports:

• liraglutide 3 mg

• 56-week weight-loss outcomes

• major obesity efficacy data

https://pubmed.ncbi.nlm.nih.gov/26132939/ 4. Davies et al.: SCALE Diabetes Evidence type: Randomized human clinical trial Supports:

• comparison of 3 mg and 1.8 mg

• dose-related weight-loss differences in people with type 2 diabetes

https://pubmed.ncbi.nlm.nih.gov/26284720/ 5. W adden et al.: SCALE Maintenance Evidence type: Randomized human clinical research Supports:

• longer-term weight maintenance

• continued liraglutide treatment after initial diet-induced weight loss

https://pubmed.ncbi.nlm.nih.gov/23812094/ 6. FDA 2026 Safety Update Evidence type: FDA regulatory action Supports:

• removal of the suicidal-behavior and ideation warning from Saxenda label-

ing https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/206321Orig1s025ltr.pdf

Final Takeaway

Liraglutide is one of the strongest-evidence compounds in this library because both its mechanism and its dosing have been studied extensively in humans.

For adult weight management, the validated Saxenda protocol is:

W eek 1: 0.6 mg daily W eek 2: 1.2 mg daily W eek 3: 1.8 mg daily W eek 4: 2.4 mg daily W eek 5 onward: 3 mg daily For type 2 diabetes, the dosing is different:

0.6 mg → 1.2 mg → up to 1.8 mg daily For timing:

once daily , any time of day , with or without food is the best-supported approach.

For cycling:

there is no established receptor-reset protocol.

For results:

Clinical: appetite changes may begin during titration, adult response is checked at 16 weeks , major obesity results are commonly measured at 56 weeks , and some longer-term research extends to 160 weeks .

And the three most important corrections to the old live page remain:

F or adult Saxenda, 1.8 mg is not the standard maintenance dose. It is part of titration.

2.4 mg should not be called a “fat-loss threshold. ” It is the week-4 titration dose.

Suicidal behavior or suicidal ideation should no longer appear as a current Saxenda warning or risk flag.

Navaro Compounds.pdf, pages 78–122.

Storage

Formulation / Stability / Sterility Logic

Approved liraglutide is already supplied as a:

ready-to-use liquid It does not need to be mixed with bacteriostatic water.

Saxenda 18 mg / 3 mL which equals:

6 mg/mL in a prefilled pen.

V erdict Do not copy research-vial mixing instructions onto approved Saxenda or liraglutide pens.

Formulation / Stability / Sterility

Saxenda

18 mg in 3 mL 6 mg/mL Clear, colorless liquid Single-patient-use prefilled pen Subcutaneous use only

Before First Use

Store refrigerated at:

2°C to 8°C (36°F to 46°F)

Do not freeze.

After First Use

A Saxenda pen can be stored for:

30 days either:

• at 15°C to 30°C (59°F to 86°F)

• or refrigerated at 2°C to 8°C (36°F to 46°F)

Keep the cap on.

Protect from:

• excessive heat

• sunlight

Remove the needle after every injection.

Discard the pen after:

30 days even if medication remains.

Supplied Navaro reference

Research Sources

Use clean canonical URLs in production .

1. DailyMed: Saxenda Evidence type: Current FDA-approved labeling Supports:

• weight-management indication

• 0.6 → 3 mg escalation

• adult 3 mg maintenance

• once-daily SC route

• meal-independent timing

• contraindications

• current warnings

• 16-week adult response check

• formulation

• storage

• 30-day in-use period

• current 2026 warning structure

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 2. DailyMed: Victoza Evidence type: FDA-approved diabetes labeling Supports:

• 0.6 mg starting dose

• 1.2 mg treatment dose

• optional increase to 1.8 mg

• once-daily SC use

• any-time-of-day dosing

• meal-independent dosing

• type 2 diabetes indication

• cardiovascular-risk reduction in adults with type 2 diabetes and estab-

lished cardiovascular disease

• approximately 13-hour half-life

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 3. Pi-Sunyer et al.: SCALE Obesity and Prediabetes Evidence type: Randomized human clinical trial

Supports:

• liraglutide 3 mg

• 56-week weight-loss outcomes

• major obesity efficacy data

https://pubmed.ncbi.nlm.nih.gov/26132939/ 4. Davies et al.: SCALE Diabetes Evidence type: Randomized human clinical trial Supports:

• comparison of 3 mg and 1.8 mg

• dose-related weight-loss differences in people with type 2 diabetes

https://pubmed.ncbi.nlm.nih.gov/26284720/ 5. W adden et al.: SCALE Maintenance Evidence type: Randomized human clinical research Supports:

• longer-term weight maintenance

• continued liraglutide treatment after initial diet-induced weight loss

https://pubmed.ncbi.nlm.nih.gov/23812094/ 6. FDA 2026 Safety Update Evidence type: FDA regulatory action Supports:

• removal of the suicidal-behavior and ideation warning from Saxenda label-

ing https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/206321Orig1s025ltr.pdf

Final Takeaway

Liraglutide is one of the strongest-evidence compounds in this library because both its mechanism and its dosing have been studied extensively in humans.

For adult weight management, the validated Saxenda protocol is:

W eek 1: 0.6 mg daily W eek 2: 1.2 mg daily W eek 3: 1.8 mg daily W eek 4: 2.4 mg daily W eek 5 onward: 3 mg daily For type 2 diabetes, the dosing is different:

0.6 mg → 1.2 mg → up to 1.8 mg daily For timing:

once daily , any time of day , with or without food is the best-supported approach.

For cycling:

there is no established receptor-reset protocol.

For results:

Clinical: appetite changes may begin during titration, adult response is checked at 16 weeks , major obesity results are commonly measured at 56 weeks , and some longer-term research extends to 160 weeks .

And the three most important corrections to the old live page remain:

F or adult Saxenda, 1.8 mg is not the standard maintenance dose. It is part of titration.

2.4 mg should not be called a “fat-loss threshold. ” It is the week-4 titration dose.

Suicidal behavior or suicidal ideation should no longer appear as a current Saxenda warning or risk flag.

Navaro Compounds.pdf, pages 78–122.